Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deciphering the genetic link between familial hypobetalipoproteinemia and neuromuscular disorder: a case report.

Journal of medical case reports·2026
Same author

Cardiotoxicity of Antibody-Drug Conjugates in HER2-Positive Cancer: Beyond Left Ventricular Ejection Fraction Decline.

Cardiology in review·2026
Same author

DOAC Pharmacokinetics in Malabsorptive States.

Cardiology in review·2026
Same author

Cardiac Biomarkers and Multimodality Imaging in Surveillance During Oncologic Therapy: An Integrated Approach to Cardio-Oncology.

Cardiology in review·2026
Same author

Cardiac Arrhythmias Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Cardiology in review·2026
Same author

Pre-emptive and Prophylactic Strategies to Prevent Cardiovascular and Neurotoxicity in Chimeric Antigen Receptor T-Cell Therapy: The Role of Tocilizumab, Anakinra, and Cytokine-Targeted Interventions.

Cardiology in review·2026

Related Experiment Video

Updated: Jun 4, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Immune Checkpoint Inhibitor-Associated Myocarditis: Current Understanding of Clinical Presentation and Management.

Jatin Thukral1, Pyush Moudgil2, Jairul Rohewal2

  • 1From the Department of Internal Medicine, New York Medical College/Landmark Medical Center, Woonsocket, RI.

Cardiology in Review
|March 31, 2026
PubMed
Summary

Immune checkpoint inhibitors (ICIs) can cause myocarditis, a severe heart condition. Early diagnosis and corticosteroid treatment are crucial for managing this rare but life-threatening ICI side effect.

Keywords:
cancer immunotherapycardio-oncologycardiotoxicityimmune checkpoint inhibitorsimmune-related adverse eventsmyocarditis

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

936

Related Experiment Videos

Last Updated: Jun 4, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.7K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

936

Area of Science:

  • Cardiology
  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment.
  • However, ICIs are linked to immune-related cardiovascular toxicities, notably myocarditis.
  • ICI-associated myocarditis is a rare but severe and potentially fatal cardiac event.

Purpose of the Study:

  • To review the clinical presentation, pathogenesis, diagnosis, and management of ICI-associated myocarditis.
  • To highlight the increasing clinical burden of myocarditis with broader ICI use.
  • To discuss challenges in diagnosis and management, including rechallenge decisions.

Main Methods:

  • Literature review focusing on ICI-associated myocarditis.
  • Analysis of pathogenesis, diagnostic modalities, and treatment strategies.
  • Synthesis of current evidence on clinical outcomes and management guidelines.

Main Results:

  • ICI-associated myocarditis presents with arrhythmias, conduction disturbances, and heart failure, often with preserved ejection fraction.
  • Pathogenesis involves T-cell activation and shared tumor-cardiac antigens, with higher risk in dual ICI therapy.
  • Diagnosis requires a multimodal approach due to nonspecific symptoms and limitations of early imaging.

Conclusions:

  • Early recognition and prompt high-dose corticosteroid treatment improve outcomes for ICI-associated myocarditis.
  • Steroid-refractory cases may need additional immunomodulatory therapies.
  • Managing ICI rechallenge requires balancing oncologic benefits against cardiac risks.